Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01246076 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01246076 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 24 participants.
The verdict
NCT01246076, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the proportion of confirmed responses (complete response, partial response, and hematologic improvement as defined by revised IWG criteria during the 12 months of treatment.
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01246076
The ClinicalTrials.gov registry entry for NCT01246076 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT01246076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01246076 about?
NCT01246076 is a clinical study titled "Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents". The purpose of this study is to determine the proportion of confirmed responses (complete response, partial response, and hematologic improvement as defined by revised IWG criteria during the 12 months of treatment.
What is the current status of trial NCT01246076?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2011-06. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01246076?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01246076?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.